Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Payables (2016 - 2025)

Historic Payables for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Q3 2025 value amounting to $4.6 million.

  • Lineage Cell Therapeutics' Payables rose 163.06% to $4.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.6 million, marking a year-over-year increase of 163.06%. This contributed to the annual value of $5.4 million for FY2024, which is 1328.55% down from last year.
  • Latest data reveals that Lineage Cell Therapeutics reported Payables of $4.6 million as of Q3 2025, which was up 163.06% from $4.5 million recorded in Q2 2025.
  • In the past 5 years, Lineage Cell Therapeutics' Payables ranged from a high of $28.0 million in Q4 2021 and a low of $4.5 million during Q2 2025
  • Over the past 5 years, Lineage Cell Therapeutics' median Payables value was $5.4 million (recorded in 2024), while the average stood at $7.2 million.
  • Its Payables has fluctuated over the past 5 years, first surged by 31052.4% in 2021, then plummeted by 6922.31% in 2022.
  • Quarter analysis of 5 years shows Lineage Cell Therapeutics' Payables stood at $28.0 million in 2021, then tumbled by 69.22% to $8.6 million in 2022, then fell by 27.16% to $6.3 million in 2023, then fell by 13.29% to $5.4 million in 2024, then decreased by 16.31% to $4.6 million in 2025.
  • Its Payables stands at $4.6 million for Q3 2025, versus $4.5 million for Q2 2025 and $5.0 million for Q1 2025.